Peru will host five of the large clinical trials to find a vaccine against SARS-CoV-2, the virus that causes COVID-19, after confirming that four other international laboratories are preparing to start studies similar to those already carried out by the Chinese Sinopharm in the country.
The Ministry of Health (Minsa) announced on Thursday the tests of the Anglo-Swedish laboratory Oxford-AstraZeneca, the American Johnson & Johnson, the German CureVac and the English Imperial College. Dr. Carlos Castillo, Immunization Advisor at the Minsa, stressed that these studies will allow greater assurance that the vaccine it will work in the Peruvian population.
They guarantee safety
Castillo said that Peru guarantees test securitySince the Minsa has an ethics committee that approves and monitors them, the General Directorate of Medicines, Supplies and Drugs (Digemid) “ensures quality and safety” and the National Institute of Health (INS) “follows the part administrative “.
The Minsa added that the objective of these tests “is that Peru and the world have safe, effective and quality vaccines. “
In this sense, the Peruvian health authorities recalled that Sinopharm It already began its studies in the country at the beginning of this month with the enrollment of 6,000 volunteers, some of whom have already received the vaccine.
It is planned that the clinical trials of the Anglo-Swedish alliance AstraZeneca-University of Oxford begin during the first week of October in the country.
The american Johnson & Johnson It will also do the same at the beginning of October, with studies in Lima, the Amazon region of Loreto and the Callao province of Lima.
In November the German laboratory is expected CureVac start its clinical trials in Lima, while the English Imperial College plans to carry out its trials in Lima and in the southern region of Moquegua from January 2021. Castillo said that other international laboratories could join this list in the coming days.
The numbers of the pandemic
The latest official report of the Minsa indicated that Peru, which is the sixth country in the world most affected by pandemic, detected another 923 cases of COVID-19 in the last hours, reaching a total of 788,930 infected since the first case in the country was reported on March 6.
However, the number of recovered also amounted to 644,345, while the deaths reached 31,938, after the report of another 68 deaths, so that the active cases in the country are 112,647, 1,689 less than in the previous report. Of the total number of patients, 8,594 are hospitalized and 1,382 remain in intensive care units (ICU).
Despite the decline in impact of the disease In the country, the former Minister of Health Víctor Zamora warned that if prevention measures are relaxed, it is very likely that there will be a re-outbreak in cities like Lima, where a large part of the population has not yet been affected by the epidemic.
Zamora indicated on the radio station Exitosa that “worldwide” it is not yet known when the call is reached “herd immunity”, which implies that a large part of the population of a locality has already been subjected to the virus and generated antibodies.
“We don’t have those numbers, so anyone who thinks we are nearing the end of the pandemic is not saying the right thing. The odds of a second regrowth in Lima they are very high, “he said.
Although the former minister added that in other cities of the country, such as the Amazonian Iquitos, a greater number of infections have already occurred, he was against allowing the reopening of clubs and bars as part of the economic reactivation of the country.
Effects of COVID-19
On the other hand, the Minsa pointed out that almost seven months after the first case of COVID-19 in the country, it is known that the disease, in addition to affecting the respiratory system, “could also leave sequelae in the nervous system, cardiovascular and even psychological disorders have been documented “.
The Minsa assured that for this reason, “a set of techniques and procedures has been designed in patient treatment who suffered from COVID-19 and have disabilities of various types and degrees. “